FDA flags Presource kits containing BD Alaris pump infusion sets with revised performance data
The FDA has issued an Early Alert after Cardinal Health identified Presource convenience kits that may contain BD Alaris Pump Infusion Sets affected by a separate recall. The alert centers on a device-performance problem, not a drug safety signal: certain pump sets with restrictive design elements are performing worse than previously disclosed, especially at very low infusion rates and low bolus volumes.
In practical terms, that means a set used to deliver a drug or fluid may not behave the way clinicians expect when the margin for error is already thin. In neonates, pediatrics, and critically ill patients, even small deviations can matter because these groups often receive antiarrhythmics, vasopressors, and other medications delivered in tiny amounts over tightly controlled intervals.
Cardinal Health sent affected customers updated use instructions on September 23. The FDA is treating the issue as potentially high risk while reviewing additional information and will update the alert if new details emerge.
Where the risk sits in the infusion chain
The concern arises from the interaction between the pump and the infusion set, particularly when the tubing includes restrictive components such as a closed male luer, filters, check valves, Y-sites, or microbore tubing. BD has continued testing these sets and determined that previously claimed performance had been overestimated in some cases, with performance sometimes substantially worse than earlier disclosures suggested.
The most vulnerable operating conditions are low programmable rates, especially under 1 mL/h, and low bolus volumes at or under 5 mL. In those ranges, a pump may under-infuse or over-infuse, delay an occlusion alarm, or deliver a bolus that differs from what the user anticipated. None of those failures require dramatic device malfunction to become clinically meaningful; a small numeric drift can become a bedside hazard when the delivered medication is a pressor, an antiarrhythmic, or a sedative titrated to a narrow target.
A delayed alarm is not a benign technical quirk.
The alert also emphasizes that these performance changes may not be readily detected by users. In a busy procedural or inpatient setting, that creates a dangerous gap between what the pump appears to be doing and what the patient is actually receiving. The risk is amplified when staff assume set behavior based on older performance information rather than the revised disclosures now being circulated.
Updated instructions for hospitals using affected kits
Cardinal Health advised customers to identify affected inventory and review the Pump Infusion Set Performance Disclosures in BD’s customer letter before deciding whether any adjustments are needed in clinical use, set selection, or pump use. If the identified infusion sets are not clinically appropriate for a given case, the guidance points clinicians toward an alternative pump, such as the BD Alaris Syringe Module or another syringe pump when Alaris is unavailable.
If no syringe pumps are available, the recalled pump infusion sets may still be used with caution, but only with enhanced clinical monitoring and adherence to previously communicated warnings. That instruction reflects the reality of hospital operations: device replacement is not always instantaneous, and clinicians may need a controlled fallback strategy while inventory is reconfigured.
The alert also reiterates mitigation steps from the BD Alaris Infusion System User Manual, including keeping the solution container within a defined height range relative to the pump, ensuring tubing is properly aligned over the pressure sensors during loading, and confirming that clamps are open and tubing is free of kinks or collapses. For low-rate infusions, pressure-mode settings above 50 mmHg are discouraged when rates are below 10 mL/h.
For occlusion management, the alert directs users to turn fluid flow to the patient off before clearing the occlusion and to consider disconnecting the tubing through a stopcock if present to relieve excess pressure. BD also cautions clinicians to weigh the risk of disconnection against the risk of an unintended bolus.
Why low-dose infusions make this alert clinically serious
This problem sits at the intersection of engineering tolerance and bedside physiology. When a medication is delivered at a high rate, a modest deviation may be easier to detect and sometimes easier to absorb clinically. At very low flow rates, however, the same absolute error can represent a much larger proportion of the intended dose, and the patient may have little physiologic reserve if the medication is a hemodynamic support agent or a narrow-therapeutic-index drug.
Delayed time to occlusion alarm matters for the same reason. If a line is partially obstructed, the pump’s warning is only useful if it arrives early enough to prevent a prolonged interruption or an inaccurate catch-up bolus. In a neonate or critically ill patient, those errors can translate into unstable blood pressure, rhythm disturbance, or a sudden change in sedation depth.
FDA’s alert states that, as of August 19, 2026, BD had not reported serious injuries or deaths tied to this issue. That is reassuring, but it does not remove the hazard from the clinical workflow. Device problems often become visible first as near misses, unit-level workarounds, or unexplained variability in delivery rather than as immediate sentinel events.
What clinicians and supply teams need to track now
The most immediate operational task is inventory control. Facilities need to know whether Presource kits contain affected infusion sets and whether those kits are being used in settings where low-rate or low-volume infusion is routine. Surgical areas, intensive care units, neonatal services, and pediatric wards may face the greatest exposure because those sites commonly rely on precise delivery of small medication volumes.
The FDA also points users to UDI resources, which can help identify specific devices more quickly and support more accurate adverse event reporting. That matters when the issue spans packaged convenience kits rather than a single isolated pump model, because traceability determines how quickly a hospital can pull or segregate stock.
For clinicians, the safest next step is not to assume that a familiar pump set still behaves exactly as before. The revised performance disclosures change the dosing conversation at the bedside, especially when the difference between adequate therapy and overcorrection may hinge on a few milliliters per hour.
The agency will continue updating the alert as more information becomes available, and the related BD recall remains the central reference for product-specific details and device performance warnings.